A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Clinical Cancer Research|2019Cited by 101
Deux ans de RCP nationale neurofibromatoses: émergence des anti-MEKA. Jannic, P. Wolkenstein, O. Zehou et al.|Annales de Dermatologie et de Vénéréologie|2020Cited by 0
Table S3 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Table S4 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Table S5 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0